Aethlon Medical (Nasdaq:
$AEMD) Announces Upcoming September Investor And Industry Conferences
SAN
DIEGO - September 6, 2016 (Investorideas.com newswire) Aethlon Medical, Inc. (Nasdaq:
AEMD), announced today its upcoming conference schedule for
the month of September. Aethlon management will be presenting at the following
conferences and is available for one-on-one meetings at the events. Additional
details, including presentation and webcast information will be announced in
the future, and will be posted on the investor relations section of the Aethlon
website at www.aethlonmedical.com.
September
11-13, 2016
Rodman & Renshaw 18th Annual Global Investment Conference
New York, NY
Presentation: Tuesday, September 13, 2:10 PM ET
September
20-22, 2016
Aegis Capital 2016 Annual Growth Conference
Las Vegas, NV
Presentation: Wednesday, September 21, 2:25 PM ET
September
26-28, 2016
Robins Equity Research Conference
Portland, OR
Presentation: Tuesday, September 27, 1:00 PM ET
September
29-30, 2016
3rd Annual Liquid Biopsies and Minimally-Invasive Diagnostics 2016
San Diego, CA
Presentation: Friday, September 30, 3:00 PM ET
About Aethlon Medical
Aethlon
Medical (AEMD) is a leading developer of immunotherapeutic technologies to
combat infectious disease and cancer. To augment the body's natural immune
defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets
that are often shielded from the immune system and not well addressed by
traditional drug therapies. The technology captures circulating viruses,
bacterial toxins and cancer promoting exosomes through affinity attachment to a
unique structure that cloaks these targets from immune detection. At present,
the Hemopurifier® is being advanced under an FDA approved clinical study.
Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused
on the discovery of exosomal biomarkers to diagnose and monitor
life-threatening diseases. Aethlon is part of the Russell Microcap® Index.
Additional information can be found online at www.AethlonMedical.com or you can connect
with us on Twitter, LinkedIn, Facebook and Google+.
The Hemopurifier® in Cancer
Upwards
of ninety percent of all cancer-related deaths are attributed to metastasis;
the spread of cancer from a primary site of origin to other organs or areas of
the body. The mechanism of how tumors metastasize to distant sites in the body
has long been one of cancer's greatest mysteries. That mystery was recently
solved when circulating particles known as tumor-derived exosomes were
discovered to be the seeds that promote the spread and growth of cancer
metastasis.
Aethlon
initiated its tumor-derived exosome research at a time when the medical
community believed exosomes were merely cellular debris with no biological
function. Today, a therapeutic to address tumor-derived exosomes represents a
significant unmet need in cancer care. Aethlon has demonstrated that the
affinity mechanism of the Hemopurifier® can capture tumor-derived exosomes
underlying several forms of cancer, including breast, ovarian and metastatic
melanoma.
Beyond
their role in metastasis, researchers have also published mounting evidence
that tumor-derived exosomes contribute to tumorigenesis (the formation of
cancer), cancer progression, angiogenesis (creation of blood vessels to fuel
tumor growth), immune evasion, and resistance to radiation and chemotherapeutic
drugs. Recent discoveries also reveal that exosomes may contribute to bacterial
and viral pathogenesis, the progression of Alzheimer and Parkinson's diseases,
the spread of prion proteins, and numerous inflammatory conditions.
The Hemopurifier® in Infectious Disease
Emerging
pathogens pose a significant threat to mankind. Of the hundreds of viral
pathogens known to be infectious to man, only a few are addressed with proven
antiviral drug or vaccine therapies. Beyond the looming threat of bioterrorism,
a proliferation of international travel, urban crowding and global warming is
expected to accelerate the emergence of future pandemics. In response, the U.S.
Department of Health and Human Services (HHS) has established an initiative to
support platform technology medical countermeasures with broad-spectrum
capabilities. Based on preclinical studies and human treatment experiences, the
Aethlon Hemopurifier® defines this initiative.
To
date, Hemopurifier therapy has been administered to individuals infected with
Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus
(HIV). In the case of Ebola, a remarkable response to a single administration
of Hemopurifier therapy (comatose physician with multiple organ failure at the
time), led to Time Magazine naming the Hemopurifier to be one of the "Top
25 Inventions" as well as one of the "Eleven Most Remarkable Advances
in Healthcare."
Beyond
human treatment experiences, pre-clinical Hemopurifier studies have validated
the broad-spectrum capture of numerous viral threats. These include:
Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox,
which serve as models for human Smallpox infection. Specific to pandemic
influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1
swine flu, and the reconstructed 1918 influenza virus, which represents a model
for the strain of influenza that killed an estimated 50 million victims in 1918
and 1919. In vitro studies of other viral threats are ongoing.
Aethlon
has also demonstrated that the Hemopurifier captures the bacteria toxins
lipopolysaccharide (LPS) and lipoteichoic acid (LTA). These studies were
conducted under a contract with the Defense Advanced Research Projects Agency
(DARPA) related to the treatment of sepsis.
About Exosome Sciences
Exosome
Sciences, Inc., in collaboration with majority shareholder Aethlon Medical
(Nasdaq: AEMD), is focused on the discovery of exosomal biomarker candidates to
diagnose and monitor life-threatening diseases. The proprietary Enzyme-Linked
Lectin-Specific Assay (ELLSA™) serves as a platform to isolate exosomal
biomarkers from a wide-range of bodily fluids. In preliminary studies, ELLSA™
demonstrated the ability to isolate exosomes from urine, which resulted in
high-sensitivity detection of HIV-infection. Specific to neurological
disorders, Exosome Sciences discovered TauSome™, an exosomal biomarker that may
be the first non-invasive candidate to detect Chronic Traumatic Encephalopathy
(CTE) in living individuals. In a study of former National Football League
(NFL) players, TauSome levels were found to be significantly higher as compared
to athlete control subjects who participated in non-contact sports. TauSome
levels also correlated with cognitive decline based standardized tests of
memory and psychomotor speed. Visit www.exosomesciences.com for additional
details.
This
press release contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 that involve risks and uncertainties. Statements containing words
such as "may," "believe," "anticipate,"
"expect," "intend," "plan," "project,"
"will," "projections," "estimate," or similar
expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. Factors that may contribute to such differences include,
without limitation, the Company's ability to maintain its listing on the Nasdaq
Capital Market, or any other national securities exchange, that the Company or
its subsidiary will not be able to commercialize its products, that the FDA
will not approve the initiation or continuation of the Company's clinical
programs or provide market clearance of the Company's products, including any
products relating to the Zika virus, the Company's ability to raise capital
when needed, the Company's ability to complete the development of its planned
products, the Company's ability to manufacture its products either internally
or through outside companies, the impact of government regulations, patent
protection on the Company's proprietary technology, the ability of the Company
to meet the milestones contemplated in its contract with DARPA, product
liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. The foregoing list of risks and
uncertainties is illustrative, but is not exhaustive. Additional factors that
could cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year ended
March 31, 2016, and in the Company's other filings with the Securities and
Exchange Commission. Except as may be required by law, the Company does not
intend, nor does it undertake any duty, to update this information to reflect
future events or circumstances.
Contacts:
More info on AEMD at Investorideas.com: http://www.investorideas.com/CO/AEMD/
Sign up for the
free investor news and stock alerts:
This news is published on the Investorideas.com
Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as well as
creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD August 11, 2016 – one month of PR.
News publication and social media – two thousand five hundred
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each
country.
